Search

Your search keyword '"Taixue An"' showing total 14 results
Start Over Author "Taixue An" Publisher wiley
14 results on '"Taixue An"'

1. Machine learning algorithms utilizing blood parameters enable early detection of immunethrombotic dysregulation in COVID‐19

Author

Zhaoming Zhou, Xiang Zhou, Liming Cheng, Lei Wen, Taixue An, Heng Gao, Hongrong Deng, Qi Yan, Xinlu Zhang, Youjiang Li, Yixing Liao, Xin‐zu Chen, Bin Nie, Jie Cheng, Guanhua Deng, Shengqiang Wang, Juan Li, Hanqi Yin, Mengxian Zhang, Linbo Cai, Lei Zheng, Minglun Li, Bleddyn Jones, Longhua Chen, Amir Abdollahi, Meijuan Zhou, Ping‐Kun Zhou, and Cheng Zhou

Subjects
Medicine (General), R5-920
Published
2021
Full Text
View/download PDF

2. The future of Extracellular Vesicles as Theranostics – an ISEV meeting report

Author

Carolina Soekmadji, Bo Li, Yiyao Huang, Haifang Wang, Taixue An, Chunchen Liu, Weilun Pan, Jing Chen, Lesley Cheung, Juan Manuel Falcon-Perez, Yong Song Gho, Harry B. Holthofer, Minh T. N. Le, Antonio Marcilla, Lorraine O’Driscoll, Faezeh Shekari, Tang Long Shen, Ana Claudia Torrecilhas, Xiaomei Yan, Fuquan Yang, Hang Yin, Yu Xiao, Zezhou Zhao, Xue Zou, Qian Wang, and Lei Zheng

Subjects
extracellular vesicles, biomarker, therapy, theranostic, Cytology, QH573-671
Abstract

The utilization of extracellular vesicles (EVs) in clinical theranostics has rapidly advanced in the past decade. In November 2018, the International Society for Extracellular Vesicles (ISEV) held a workshop on “EVs in Clinical Theranostic”. Here, we report the conclusions of roundtable discussions on the current advancement in the analysis technologies and we provide some guidelines to researchers in the field to consider the use of EVs in clinical application. The main challenges and the requirements for EV separation and characterization strategies, quality control and clinical investigation were discussed to promote the application of EVs in future clinical studies.

Published
2020
Full Text
View/download PDF

3. Exosomes serve as tumour markers for personalized diagnostics owing to their important role in cancer metastasis

Author

Taixue An, Sihua Qin, Yong Xu, Yueting Tang, Yiyao Huang, Bo Situ, Jameel M. Inal, and Lei Zheng

Subjects
extracellular vesicle, metastasis, malignant neoplasms, microenvironment, personalized diagnostics, cancer biomarkers, Cytology, QH573-671
Abstract

Exosomes, membrane vesicles of 40–100 nm in diameter, are derived from endosomes in various cells. The bioactive molecules specifically packed into exosomes can be horizontally transferred into recipient cells changing their biological properties, by which tumour cells continuously modify their surrounding microenvironment and distant target cells favouring cancer metastasis. It has been suspected for a long time that exosomes participate in the whole process of tumour metastasis. Although there is much unknown and many controversies in the role of cancer exosome, the major contribution of tumour-associated exosomes to different steps of cancer metastasis are demonstrated in this review. Mainly because these exosomes are easily accessible and capable of representing their parental cells, exosomes draw much attention as a promising biomarker for tumour screening, diagnosis and prognosis. Currently, researchers have found numerous biomarkers in exosomes with great potential to be utilized in personalized medicine. In this article, we summarize the roles of biomarkers, which are validated by clinical samples. Even though many conundrums remain, such as exosome extraction, large multicentre validation of biomarkers and data interpretation, exosomes are certain to be used in clinical practice in the near future as the field rapidly expands.

Published
2015
Full Text
View/download PDF

4. Featured Cover

Author

Zhao, Yujie, primary, Yang, Yang, additional, Lv, Weifu, additional, Zhu, Siyu, additional, Chen, Xiaoqiong, additional, Wang, Tao, additional, Huang, Mingsheng, additional, An, Taixue, additional, Duan, Chongyang, additional, Yu, Xiangrong, additional, Li, Qiyang, additional, Chen, Jinqiang, additional, Luo, Junyang, additional, Zhou, Shuoling, additional, Lu, Ligong, additional, Huang, Meiyan, additional, and Fu, Sirui, additional

Published
2024
Full Text
View/download PDF

5. A modified model for predicting mortality after transjugular intrahepatic portosystemic shunt: A multicentre study

Author

Zhao, Yujie, primary, Yang, Yang, additional, Lv, Weifu, additional, Zhu, Siyu, additional, Chen, Xiaoqiong, additional, Wang, Tao, additional, Huang, Mingsheng, additional, An, Taixue, additional, Duan, Chongyang, additional, Yu, Xiangrong, additional, Li, Qiyang, additional, Chen, Jinqiang, additional, Luo, Junyang, additional, Zhou, Shuoling, additional, Lu, Ligong, additional, Huang, Meiyan, additional, and Fu, Sirui, additional

Published
2023
Full Text
View/download PDF

6. Risk stratification by long non‐coding RNAs profiling in COVID‐19 patients

Author

Xiang Zhou, Xinlu Zhang, Weijun Feng, Yi Pan, Cheng Zhou, Jie Cheng, Yun Sun, Shu Zhang, Taixue An, Lei Wen, Zhaoming Zhou, Minyuan Luan, and Min Jia

Subjects
Male, RNA-Seq, macromolecular substances, Disease, Bioinformatics, Risk Assessment, Severity of Illness Index, Subclass, Transcriptome, lncRNA, COVID‐19, Severity of illness, Humans, Medicine, pulmonary injury, Aged, Aged, 80 and over, Framingham Risk Score, business.industry, Case-control study, COVID-19, RNA, Original Articles, Cell Biology, Middle Aged, Case-Control Studies, RNA‐seq, Molecular Medicine, Original Article, Female, RNA, Long Noncoding, business, transcriptome, Biomarkers
Abstract

Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has become a global pandemic worldwide. Long non‐coding RNAs (lncRNAs) are a subclass of endogenous, non‐protein‐coding RNA, which lacks an open reading frame and is more than 200 nucleotides in length. However, the functions for lncRNAs in COVID‐19 have not been unravelled. The present study aimed at identifying the related lncRNAs based on RNA sequencing of peripheral blood mononuclear cells from patients with SARS‐CoV‐2 infection as well as health individuals. Overall, 17 severe, 12 non‐severe patients and 10 healthy controls were enrolled in this study. Firstly, we reported some altered lncRNAs between severe, non‐severe COVID‐19 patients and healthy controls. Next, we developed a 7‐lncRNA panel with a good differential ability between severe and non‐severe COVID‐19 patients using least absolute shrinkage and selection operator regression. Finally, we observed that COVID‐19 is a heterogeneous disease among which severe COVID‐19 patients have two subtypes with similar risk score and immune score based on lncRNA panel using iCluster algorithm. As the roles of lncRNAs in COVID‐19 have not yet been fully identified and understood, our analysis should provide valuable resource and information for the future studies.

Published
2021
Full Text
View/download PDF

7. Machine learning algorithms utilizing blood parameters enable early detection of immunethrombotic dysregulation in COVID‐19

Author

Zhou, Zhaoming, primary, Zhou, Xiang, additional, Cheng, Liming, additional, Wen, Lei, additional, An, Taixue, additional, Gao, Heng, additional, Deng, Hongrong, additional, Yan, Qi, additional, Zhang, Xinlu, additional, Li, Youjiang, additional, Liao, Yixing, additional, Chen, Xin‐zu, additional, Nie, Bin, additional, Cheng, Jie, additional, Deng, Guanhua, additional, Wang, Shengqiang, additional, Li, Juan, additional, Yin, Hanqi, additional, Zhang, Mengxian, additional, Cai, Linbo, additional, Zheng, Lei, additional, Li, Minglun, additional, Jones, Bleddyn, additional, Chen, Longhua, additional, Abdollahi, Amir, additional, Zhou, Meijuan, additional, Zhou, Ping‐Kun, additional, and Zhou, Cheng, additional

Published
2021
Full Text
View/download PDF

9. The future of Extracellular Vesicles as Theranostics – an ISEV meeting report

Author

Soekmadji, Carolina, primary, Li, Bo, additional, Huang, Yiyao, additional, Wang, Haifang, additional, An, Taixue, additional, Liu, Chunchen, additional, Pan, Weilun, additional, Chen, Jing, additional, Cheung, Lesley, additional, Falcon‐Perez, Juan Manuel, additional, Gho, Yong Song, additional, Holthofer, Harry B., additional, Le, Minh T. N., additional, Marcilla, Antonio, additional, O'Driscoll, Lorraine, additional, Shekari, Faezeh, additional, Shen, Tang Long, additional, Torrecilhas, Ana Claudia, additional, Yan, Xiaomei, additional, Yang, Fuquan, additional, Yin, Hang, additional, Xiao, Yu, additional, Zhao, Zezhou, additional, Zou, Xue, additional, Wang, Qian, additional, and Zheng, Lei, additional

Published
2020
Full Text
View/download PDF

11. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method

Author

Yiyao Huang, Lei Zheng, Sihua Qin, Taixue An, Yong Xu, and Yue-Ting Tang

Subjects
Male, 0301 basic medicine, China, Pathology, medicine.medical_specialty, Urology, medicine.medical_treatment, Urinary system, Urine, urologic and male genital diseases, Extracellular Vesicles, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Prostate, Biomarkers, Tumor, Humans, Medicine, Dialysis, Aged, Neoplasm Staging, business.industry, Prostatic Neoplasms, Reproducibility of Results, Middle Aged, Prostate-Specific Antigen, Hyperplasia, medicine.disease, MicroRNAs, Prostate-specific antigen, 030104 developmental biology, medicine.anatomical_structure, Oncology, Research Design, 030220 oncology & carcinogenesis, Biomarker (medicine), Neoplasm Grading, business
Abstract

Background Extracellular vesicles (EVs) can be detected in body fluids and may serve as disease biomarkers. Increasing evidence suggests that circulating miRNAs in serum and urine may be potential non-invasive biomarkers for prostate cancer (PCa). In the present study, we aimed to investigate whether hydrostatic filtration dialysis (HFD) is suitable for urinary EVs (UEVs) isolation and whether such reported PCa-related miRNAs can be detected in UEVs as PCa biomarkers. Methods To analyze EVs miRNAs, we searched for an easy and economic method to enrich EVs from urine samples. We compared the efficiency of HFD method and conventional ultracentrifugation (UC) in isolating UEVs. Subsequently, UEVs were isolated from patients with PCa, patients with benign prostate hyperplasia (BPH) and healthy individuals. Differential expression of four PCa-related miRNAs (miR-572, miR-1290, miR-141, and miR-145) were measured in UEVs and paired serum EVs using SYBR Green-based quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Results The overall performance of HFD was similar to UC. In miRNA yield, both HFD and UC can meet the needs of further analysis. The level of miR-145 in UEVs was significantly increased in patients with PCa compared with the patients with BPH (P = 0.018). In addition, significant increase was observed in miR-145 levels when patients with Gleason score ≥8 tumors compared with Gleason score ≤7 (P = 0.020). Receiver-operating characteristic curve (ROC) revealed that miR-145 in UEVs combined with serum PSA could differentiate PCa from BPH better than PSA alone (AUC 0.863 and AUC 0.805, respectively). In serum EVs, four miRNAs were significantly higher in patients with PCa than with BPH. Conclusion HFD is appropriate for UEVs isolation and miRNA analysis when compared with conventional UC. miR-145 in UEVs is upregulated from PCa patients compared BPH patients and healthy controls. We suggest the potential use of UEVs miR-145 as a biomarker of PCa.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results